HIV Infection Clinical Trial
Official title:
Addressing Alcohol/HIV Consequences in Substance Dependence - Boston ARCH Cohort
The purpose of this study is to expand and continue a cohort of HIV-infected adults to establish the longitudinal Boston ARCH Cohort of 250 HIV-infected men and women with current substance dependence or ever injection drug use that have a spectrum of alcohol use; and to determine the effect of alcohol consumption on changes in bone health prospectively in the Cohort.
Unhealthy alcohol use (i.e. the spectrum ranging from heavy drinking that risks health
consequences to dependence) is common among HIV-infected persons and is associated with
worse health outcomes among people with HIV infection. However, much remains unknown about
alcohol-related health effects in those affected by multiple drugs (particularly opioids),
or about specific health effects such as detriment to bone. Alcohol use can disrupt bone
remodeling by suppressing formation and increasing resorption; heavy alcohol use is
associated with both osteopenia (low bone mineral density [BMD]) and incidence of fractures.
Osteopenia is common among HIV-infected patients, and fractures are more common in these
patients than among adults without HIV infection. Duration of HIV infection has been found
to be associated with low BMD, and antiretroviral therapy (ART) also appears to be
associated with BMD decline. While bone health is likely affected by HIV infection, ART,
alcohol and other drug (e.g. opioid) use (in addition to other known risk factors), the
alcohol-osteopenia association among those with HIV infection is not well-characterized. It
is not known whether there is an association, the magnitude and nature of that association,
and how the relationship is affected by other commonly co-occurring factors (e.g. opioid
use, ART).
Accordingly, as part of the Uganda Russia Boston Alcohol Network for Alcohol Research
Collaboration on HIV/AIDS (URBAN ARCH) Consortium, we seek to expand and continue a cohort
of HIV-infected adults to establish the Boston ARCH Cohort of 250 HIV-infected adults
affected by multiple substances and that have a spectrum of alcohol use. This observational
prospective cohort study will involve in-person assessments that will take place at 6-month
intervals; participants will be followed for a minimum of 1 year and a maximum of 3.5 years.
All assessments will include a researcher-administered questionnaire and breath alcohol
test. In addition, the baseline assessment and each annual assessment (12, 24 or 36 months
after enrollment) will also include: a urine pregnancy test (females only), blood
collection, measurement of bone mineral density of the hip and spine (using Hologic QDR
4500W enhanced-array, whole-body, dual-energy radiographic absorptiometry [Bone
Densitometer]), and measurement of bone microarchitecture of the wrist and ankle (using
Xtreme CT [a device that measures high-resolution three-dimensional peripheral quantitative
computed tomography]). We will conduct laboratory tests on blood samples collected at these
time points, including tests for 25(OH) vitamin D3 and phosphatidylethanol (PEth). Remaining
plasma and serum samples will be stored for future study of bone markers such as:
parathyroid hormone, testosterone, carboxy-terminal collagen crosslinks (CTX) (a marker of
osteoclast activity), and osteocalcin (osteoblast activity).
In summation, this study will measure the effect of alcohol consumption on changes in bone
health prospectively in HIV-infected adults with current substance dependence or ever
injection drug use. To our knowledge, no other prospective HIV/bone study has studied these
relevant factors simultaneously or used HR-pQCT to assess bone microarchitecture. Data on
alcohol risks to bone health is important information for defining risky drinking amounts
for people with HIV infection (and for advising such patients accordingly).
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01680094 -
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
|
Phase 1/Phase 2 |